URGN vs ZYME

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

URGN

60.7
AI Score
VS
URGN Wins

ZYME

48.2
AI Score

Investment Advisor Scores

URGN

61score
Recommendation
BUY

ZYME

48score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric URGN ZYME Winner
Revenue 212.42M 263.46M ZYME
Net Income -39.39M 84.52M ZYME
Net Margin -18.5% 32.1% ZYME
Operating Income -11.82M 88.30M ZYME
ROE 31.5% 32.7% ZYME
ROA -14.5% 7.2% ZYME
Total Assets 271.87M 1.18B ZYME
Cash 85.56M 100.46M ZYME
Debt/Equity -1.60 1.31 URGN
Current Ratio 3.40 3.30 URGN
Free Cash Flow -93.71M -101.99M URGN

Relative Price Performance (Last 90 Days)

URGN 1M: -29.2% · 3M: -46.3% ZYME 1M: +10.3% · 3M: +8.7%

Current Technical Phase

URGN

Markdown
Sell / avoid

Price below a falling SMA50 (slope -14.0%), weak momentum, RSI 27

RSI (14): 27.3 · Price: $25.90

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.6 · Price: $27.32

Fundamentals Snapshot

Metric URGN ZYME
Market Cap — —
Forward P/E 9.9 23.9
Trailing P/E — 59.4
Revenue (TTM) — —
Revenue Growth 2.2% 8.3%
Gross Margin 0.9% 0.5%
Operating Margin 0.1% 0.7%
EPS -1.31 0.53
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, URGN is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.